Superworth

Usana Health Sciences price to free cash flow USNA

Market value divided by free cash flow over the last twelve months, since 2012.

Today, Oct 23, 2026
16.2×
10-year median
14.0×
Against its 10-year history
74th
percentile: 0 is its lowest day, 100 its highest
10-year range
7.3× to 138×
Peer median
20.1×

Usana Health Sciences' price to free cash flow is 16.2× as of Oct 23, 2026.

That is above its ten-year median of 14.0×, higher than on 74% of days in the last ten years.

Over that time it ranged from 7.3× in Oct 2025 to 138× in Jul 2026.

The median for 8 chemicals stocks of a similar size is 20.1×.

Price to free cash flow over time

The dashed line is the 10-year median and the shaded band the middle half of its days.

Open the interactive chart, with overlays and comparisons

Year by year

YearEnd of yearLowHigh
2026 so far16.2×15.5×138×
202519.4×7.3×20.0×
202410.4×9.7×17.2×
202313.7×10.9×16.1×
202213.1×11.5×16.2×
202114.8×11.2×15.3×
202010.9×9.3×18.1×
201917.8×11.0×18.5×
201817.9×16.3×28.6×
201716.4×8.2×16.6×
20168.7×8.6×22.1×
201518.4×13.9×20.7×
201414.7×9.4×21.9×
201312.6×7.0×13.8×
20126.4×6.4×10.7×

Against its peers

Companies in Chemicals nearest Usana Health Sciences' size, closest first, today.

CompanyPrice to free cash flow
USNAUsana Health Sciences16.2×
NAGENiagen Biosciencen/m
FTLFFitlife Brands7.8×
FTKFlotek Industriesn/m
CRONCronos24.8×
BTMDbiote1.9×
ROGRogers27.0×
NGVTIngevity15.5×
IOSPInnospec34.7×
Peer median20.1×

What the price to free cash flow tells you

Market value divided by free cash flow: the cash left after running the business and paying for equipment. Cash is harder to manage than accounting earnings, so many investors trust this more than PE.

Lumpy: a big year of building factories drops cash flow and inflates the ratio without the business getting worse.

More on Usana Health Sciences

Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.